AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04013516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call
Description: A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
Study NCT04013516 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Call
Description: A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
Study NCT01729156 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1000 mg metformin twice daily in 3 months
Study NCT01729156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin twice daily in 3 months
Study NCT01729156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets twice daily in 3 months
Study NCT00577850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
Study NCT00577850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: 0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
Study NCT03538379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bleeding Control Basic (B-Con) Course
Description: The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
Study NCT02882919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself v2.0
Description: In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
Study NCT04147026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinnoTest®
Description: The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy.
Study NCT04147026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biotherapy prescription without SinnoTest® software
Description: The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
Study NCT01572701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404
Description: 20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
Study NCT03919981 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: 25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
Study NCT04603664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum NGAL and cystatin c
Description: measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
Study NCT03970551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Counter-maneuver
Description: Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
Study NCT03970551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Test
Description: Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
Study NCT03970551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
Study NCT00863863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griseofulvin 125 mg/5 mL Suspension, single dose
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
Study NCT00863863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grifulvin V® 125 mg/5 mL Suspension, single dose
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
Study NCT02693613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral
Study NCT02693613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin®
Description: Oral
Study NCT00551109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral administration, once daily for 8 weeks
Study NCT00551109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 Low
Description: Low dose, oral administration, once daily for 8 weeks
Study NCT00551109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA4503 High
Description: High dose, oral administration, once daily for 8 weeks
Study NCT03581201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory measurements
Description: Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry
Study NCT03581201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
Study NCT03581201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance analysis
Description: The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
Study NCT01361295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI with PVAC gold
Description: Pulmonary vein isolation using the Medtronic PVAC gold catheter
Study NCT01361295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI with Cooled-RF
Description: Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
Study NCT04309279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zentangle
Description: Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
Study NCT03483558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: A standardized diet without any vegetables was provided.
Study NCT03483558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach
Description: A standardized diet with 200g spinach was provided.
Study NCT03483558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celery
Description: A standardized diet with 200g celery was provided.
Study NCT03483558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onion
Description: A standardized diet with 200g onion was provided.
Study NCT03483558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Vegetables
Description: A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
Study NCT01535183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan combination chemotherapy
Description: Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna
Study NCT00438321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Study NCT00438321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Study NCT00438321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole Pill
Study NCT00438321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01695577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary evaluation and VR
Description: Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
Study NCT01695577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary evaluation
Description: Multidisciplinary assessment and evaluation.
Study NCT03670706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Package of care
Study NCT03670706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic optimisation
Description: optimisation
Study NCT00281021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Digoxin
Description: Each subject will receive erlotinib and digoxin daily until progression.
Study NCT03703245 — intervention group
Intervention type: OTHER
Intervention: Sodium bicarbonate
Description: Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
Study NCT03703245 — intervention group
Intervention type: OTHER
Intervention: Control Dentifrice
Description: Negative control dentifrice containing 0% w/w sodium bicarbonate
Study NCT03382184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Dual laser
Description: The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
Study NCT03382184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo laser
Description: The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
Study NCT01224704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Description: Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.
Study NCT01224704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water deprivation
Description: 24 hour water deprivation
Study NCT01744951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)
Study NCT01800357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of mildronate
Description: infusion of mildronate(500mg) once a day and for 14 days
Study NCT01800357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of plabcebo once a day and for 14 days
Study NCT01800357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: infusion of aspirin (100mg) once a day for days
Study NCT01800357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Description: infusion of aspirin (100mg) once a day for days
Study NCT04337333 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Two-in-one stent
Description: Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
Study NCT02300051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STPGP and RPGT
Study NCT02300051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Study NCT02300051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Study NCT01107340 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AMIStem Hip System
Study NCT01008696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
Study NCT01008696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
Study NCT04475367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App hypercross group
Description: hypertensive patients using HyperCrossApp
Study NCT04914143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: broken Ganoderma lucidum spore powder
Description: The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
Study NCT04914143 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group was treated with placebo after chemotherapy
Study NCT01176968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
Study NCT01176968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT04376970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLUCON®
Description: The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.
Study NCT04376970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A eye drops 0.5%
Description: The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
Study NCT00966823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal tracheal obstruction with detachable balloon (device)
Description: Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation.
Study NCT04317560 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: 2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
Study NCT04317560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: 2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
Study NCT04317560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin injection
Description: 2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
Study NCT04852263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group I
Description: Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
Study NCT04852263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group II (NPA group)
Description: Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
Study NCT02431650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Study NCT02431650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study NCT04888130 — intervention group
Intervention type: GENETIC
Intervention: Phylogenetic Analysis
Description: The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
Study NCT04888130 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
Study NCT01636414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemovac drain
Description: The Hemovac drain is a device placed under your skin used to collect blood during surgery.
Study NCT01636414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-infusion drain
Description: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
Study NCT01636414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic drain
Description: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
Study NCT00518414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marketed infant formula with DHA and ARA
Study NCT00518414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based infant formula with DHA and ARA
Study NCT00518414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based formula with DHA, ARA, prebiotics
Study NCT02885298 — intervention group
Intervention type: PROCEDURE
Intervention: Upright intubation
Description: Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
Study NCT00819286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock Rigid Fixation Plates
Description: patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
Study NCT00819286 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wire (control)
Description: patients will have their sternum closed using wire (stainless steel surgical wire).